TELA Bio names Jeffrey Blizard as new president

MALVERN, Pa. - TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company with a market capitalization of approximately $55 million, has announced the immediate appointment of Jeffrey Blizard as its new President. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations, despite facing profitability challenges. Blizard, who has been part of TELA Bio’s Board of Directors for the past year, is taking on this role with a wealth of experience from his tenure in the industry, including a recent position as Global Head of Surgical Sales at Abiomed, a subsidiary of Johnson & Johnson.

The company’s co-founder and CEO, Antony Koblish, expressed confidence in Blizard’s ability to lead TELA Bio through its next growth phase, citing his proven track record in scaling businesses and inspiring teams. Koblish anticipates that Blizard’s leadership will enhance the company’s commercial performance and strengthen its commitment to customers, partners, and shareholders.

Before joining TELA Bio, Blizard contributed to significant growth in Abiomed’s Surgical Division and has held commercial leadership roles at prominent medtech firms such as Medtronic, Intuitive Surgical, and Boston Scientific. His extensive experience is expected to be instrumental in accelerating TELA Bio’s execution, deepening customer relationships, and expanding the company’s impact in the market. The company has shown promising revenue growth of nearly 13% over the last twelve months, maintaining a healthy gross margin of 67.5%. InvestingPro subscribers can access 8 additional key insights about TELA’s financial health and growth prospects.

TELA Bio specializes in soft-tissue reconstruction solutions designed to optimize clinical outcomes while minimizing patients’ long-term exposure to permanent synthetic materials. The company aims to provide surgeons with advanced, economically effective solutions that leverage natural healing processes. Financial data from InvestingPro shows the company maintains strong liquidity with a current ratio of 4.22, though it faces near-term cash burn challenges. Detailed analysis of TELA’s financial position and growth potential is available in InvestingPro’s comprehensive research report, part of its coverage of over 1,400 US stocks.

This leadership change comes at a critical juncture for TELA Bio as the company seeks to amplify its market presence and deliver value through its differentiated portfolio.

The announcement of Blizard’s appointment is based on a press release statement from TELA Bio. The company has cautioned that forward-looking statements within the press release are subject to risks, uncertainties, and other factors that could cause actual results to differ significantly from those projected. TELA Bio does not undertake any obligation to update forward-looking statements post the date of the press release unless required by applicable law.

In other recent news, TELA Bio reported its Q1 2025 financial results, revealing a revenue of $18.5 million, which fell short of the expected $21.05 million. Despite the revenue miss, the company saw a 12% year-over-year growth in revenue, driven by strong demand for its OviTex product lines. TELA Bio maintained its full-year 2025 revenue guidance of $85 million to $88 million, projecting a growth of 23-27%. Analysts from Piper Sandler maintained a Neutral rating on TELA Bio, noting the company’s first-quarter performance surpassed top-line estimates but highlighted concerns about higher-than-expected spending. The firm also pointed out that TELA Bio’s strategy to enhance sales force efficiency and introduce new products could capture a larger market segment. The company’s financial outlook includes potential tariff impacts on gross margins, which could decrease by 50-100 basis points. TELA Bio’s management emphasized the importance of innovation and market leadership, with plans to launch new products and improve commercial organization efficiency.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.